Sabby Management’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-23,782
Closed -$2.53M 177
2020
Q4
$2.53M Buy
23,782
+13,375
+129% +$1.78M 0.48% 32
2020
Q3
$1.45M Buy
10,407
+10,240
+6,132% +$2.14M 0.22% 55
2020
Q2
$54K Buy
+167
New +$26.8K 0.01% 91
2016
Q1
Sell
-51,599
Closed -$4.16M 321
2015
Q4
$4.16M Sell
51,599
-9,864
-16% -$785K 0.23% 72
2015
Q3
$4.26M Sell
61,463
-14,037
-19% -$1.22M 0.18% 96
2015
Q2
$7.39M Buy
+75,500
New +$8.07M 0.27% 72

Other funds holding INO

Sabby Management's INO Position: Q1 2021 in Review

Sabby Management sold out of Inovio Pharmaceuticals (INO) in Q1 2021, closing a stake of 23,782 shares — an estimated $2.53M sold.

Sabby Management first reported a position in INO in Q2 2015 and held it in 6 quarters. The position peaked at $7.39M in Q2 2015. 218 funds tracked by Wall St. Rank hold INO as of Q1 2021.

  • Sabby Management reported no remaining Inovio Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 23,782 Inovio Pharmaceuticals shares in Q1 2021, an estimated $2.53M.
  • Sabby Management first reported a position in Inovio Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Sabby Management's Inovio Pharmaceuticals position peaked at $7.39M in Q2 2015.
  • 218 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.